The history of the hepatitis B vaccine has been marked by controversies, from the ‘Australia antigen’ to the ‘Pediatric ...

Switching to a long-acting cabotegravir/rilpivirine antiretroviral regimen may be safe for patients with HIV who have prior hepatitis B virus exposure, a real-world study shows.

Background and aims The rate of functional cure (HBsAg loss) remains unsatisfactory following pegylated interferon (PEG-IFN) treatment in chronic hepatitis B. To optimize PEG-IFN administration, this ...